Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.79 | N/A | -35.40% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.79 | N/A | -35.40% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current financial performance and highlighted the importance of continued investment in their pipeline. They did not offer specific guidance for the upcoming quarters.
Management acknowledged challenges in achieving profitability.
They emphasized ongoing investment in research and development.
No specific guidance was provided for future performance.
Ultragenyx Pharma's earnings report indicates a significant miss on EPS, which contributed to a 4.48% drop in stock price. The lack of revenue figures and guidance adds uncertainty for investors. The company's focus on R&D suggests they are prioritizing long-term growth over short-term profitability.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BRIXMOR PPTY GROUP I REIT